16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc

L & S Advisors Inc bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 16,893 shares of the company’s stock, valued at approximately $877,000.

Several other institutional investors also recently bought and sold shares of BBIO. Strs Ohio lifted its position in shares of BridgeBio Pharma by 1.1% during the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock worth $966,000 after purchasing an additional 200 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after purchasing an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after buying an additional 228 shares during the period. Gabelli Funds LLC increased its stake in BridgeBio Pharma by 0.3% during the 2nd quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock worth $3,185,000 after buying an additional 250 shares during the period. Finally, Main Management ETF Advisors LLC lifted its holdings in BridgeBio Pharma by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company’s stock worth $981,000 after buying an additional 372 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley began coverage on shares of BridgeBio Pharma in a research note on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price target for the company. Raymond James Financial set a $89.00 target price on BridgeBio Pharma and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Leerink Partners increased their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Oppenheimer lifted their price objective on BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Finally, Piper Sandler upped their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.05.

Insider Activity at BridgeBio Pharma

In related news, Director Randal W. Scott sold 10,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the transaction, the director directly owned 11,589 shares of the company’s stock, valued at $874,505.94. This trade represents a 46.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $74.40, for a total transaction of $2,976,000.00. Following the sale, the chief executive officer owned 775,686 shares in the company, valued at $57,711,038.40. This represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 176,121 shares of company stock worth $13,009,631. Corporate insiders own 18.20% of the company’s stock.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results in achondroplasia improve the drug candidate’s regulatory and commercial outlook — a clear catalyst lifting investor expectations and valuation. Read More.
• Positive Sentiment: HC Wainwright boosted EPS estimates across Q2–Q4/FY2026 and raised its price target to $100 while keeping a Buy rating, adding analyst conviction behind further upside. Read More.
• Positive Sentiment: Broad Wall Street support (multiple Buy/Overweight ratings and higher targets) provides additional demand if upcoming clinical/financials meet expectations. Read More.
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 call — this scheduled event can cause short‑term volatility depending on revenue, cash burn and program updates. Read More.
• Neutral Sentiment: The company granted inducement RSUs (76,701 shares across 34 hires) — modest near‑term share‑based compensation to monitor for dilution. Read More.
• Neutral Sentiment: Oppenheimer added a small new 13F position (7,845 shares) — a modest institutional buy that signals some investor interest but is not yet material. Read More.
• Neutral Sentiment: Automated short‑interest reporting here shows inconsistent/zero figures (likely a reporting artifact); current short interest does not appear to be a material near‑term factor.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO and CAO reported sales the same day — concentrated executive disposals can weigh on near‑term sentiment. Read More.
• Negative Sentiment: Ongoing pattern of executive selling highlighted in coverage — repeated insider liquidity events may keep downward pressure until insiders rebuild meaningful ownership. Read More.

BridgeBio Pharma Stock Down 4.3%

BBIO stock opened at $70.72 on Friday. The stock has a market cap of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13. BridgeBio Pharma, Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $84.94. The business has a 50 day moving average price of $75.66 and a 200 day moving average price of $63.84.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.